The Efficiency of Proanthocyanidin in an Experimental Pulmonary Fibrosis Model: Comparison with Taurine
- 187 Downloads
Pulmonary fibrosis (PF) is a progressive fatal disorder. Bleomycin (BLM) is a widely used chemotherapeutic agent causing PF. Numerous agents have been investigated to prevent the progression of PF so far, but there is still a need to find more efficacious agents. Proanthocyanidin (PA) is a strong antioxidant, the main ingredient of grape seed extract. Since PA is ready for use in practice, we aimed to compare the preventive effect of PA in comparison with taurine (Tau) in BLM-induced PF. Forty Wistar male albino rats were used in the study and were divided into four groups: group 1, control; group 2, BLM-induced PF group; group 3, BLM-induced PF and treated with PA group; and group 4, BLM-induced PF and treated with Tau group. Treatments were begun 10 days before and continued 21 days after BLM injection. PA and Tau effectively inhibited inflammation, edema, severity of fibrosis, fibrosis extension, inflammatory cell accumulation, iNOS staining, and hydroxyproline level as well (p < 0.05). Total histological scores of the PA group were similar to the control group; Tau was significantly higher than the control group but lower than the BLM group (p < 0.05). We believe that PA could be a new treatment choice for PF, but further studies need to be conducted to verify the findings of the current study.
KEY WORDSbleomycin proanthocyanidin pulmonary fibrosis iNOS hydroxyproline inflammation
The authors would like to thank Patricia B. Upton for the critical reading of the manuscript.
Conflict of Interest
The authors declare that there are no conflicts of interest.
- 23.Demedts, M., A.U. Wells, J.M. Antó, U. Costabel, R. Hubbard, P. Cullinan, H. Slabbynck, G. Rizzato, V. Poletti, E.K. Verbeken, M.J. Thomeer, J. Kokkarinen, J.C. Dalphin, and A.N. Taylor. 2001. Interstitial lung diseases: An epidemiological overview. The European Respiratory Journal. Supplement 32: 2s–16s.PubMedGoogle Scholar
- 29.Jakubzick, C., E.S. Choi, B.H. Joshi, M.P. Keane, S.L. Kunkel, R.K. Puri, et al. 2003. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. Journal of Immunology 171: 2684–2693.Google Scholar
- 44.Aruoma, O.I., B. Sun, H. Fujii, V.S. Neergheen, T. Bahorun, K.S. Kang, et al. 2006. Low molecular proanthocyanidin dietary biofactor Oligonol: Its modulation of oxidative stress, bioefficacy, neuroprotection, food application and chemoprevention potentials. BioFactors 27: 245–265.PubMedCrossRefGoogle Scholar